UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 11, 2019

 

Millendo Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code: (734) 845-9000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

 

 

Item 1.01.  Entry into a Material Definitive Agreement.

 

New Office Lease

 

On April 11, 2019, Millendo Therapeutics, Inc. (the “Company”) and Elandzee Trust under declaration of Trust dated March 27, 1972 (the “Landlord”) entered into a Flex Space Agreement effective as of April 11, 2019 (the “Lease”), pursuant to which the Company will lease approximately 4,058 rentable square feet located at 420 Bedford Street, Lexington, Massachusetts (the “Premises”). The Company plans to occupy the Premises beginning in May 2019 and intends to establish a commercial organization in the Boston area. The Lease term begins on April 15, 2019 and ends on September 30, 2020. The Landlord will not charge the Company rent for the month of April 2019. From May 1, 2019 through August 31, 2019, the monthly rent will be $7,875.00. Commencing on September 1, 2019, through the end of the term expiring on September 30, 2020, the monthly rent will be $10,652.25. The Company has the right to terminate the Lease at any time and for any reason upon sixty (60) days prior written notice to the Landlord. The Lease does not provide for extension or renewal.

 

The foregoing summary of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a full copy of which is filed as an exhibit to this Report.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)    Exhibits

 

Exhibit No.		Description
10.1		Lease Agreement.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	MILLENDO THERAPEUTICS, INC.
Date: April 17, 2019	By:	/s/ Julia C. Owens, Ph.D.
		Julia C. Owens, Ph.D.
		President and Chief Executive Officer

 

3